Float Short %

9.85

Margin Of Safety %

Put/Call OI Ratio

0.34

EPS Next Q Diff

0.05

EPS Last/This Y

-0.17

EPS This/Next Y

-0.03

Price

0.05

Target Price

0.28

Analyst Recom

3.67

Performance Q

-77.23

Relative Volume

1.67

Beta

2.26

Ticker: ADAP

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	ADAP	0.0596	0.11	6.29	7523
2025-08-18	ADAP	0.0713	0.03	1.09	6146
2025-08-19	ADAP	0.062	0.11	4.49	7206
2025-08-20	ADAP	0.058	0.17	999.99	7649
2025-08-21	ADAP	0.0597	0.22	37.70	7948
2025-08-22	ADAP	0.0572	0.26	6.88	8246
2025-08-25	ADAP	0.0601	0.31	1.06	8572
2025-08-26	ADAP	0.058	0.32	15.00	8844
2025-08-27	ADAP	0.0579	0.34	0.96	8960
2025-08-28	ADAP	0.0689	0.35	3.70	9219
2025-08-29	ADAP	0.059	0.36	102.40	9555
2025-09-02	ADAP	0.0564	0.33	0.00	9323
2025-09-03	ADAP	0.0526	0.33	6.96	9332
2025-09-04	ADAP	0.0505	0.35	2.22	9508
2025-09-05	ADAP	0.042	0.35	0.00	9524
2025-09-08	ADAP	0.0431	0.35	0.05	9578
2025-09-09	ADAP	0.0494	0.35	0.02	9667
2025-09-10	ADAP	0.0504	0.34	0.04	9791
2025-09-11	ADAP	0.0506	0.34	0.10	9871
2025-09-12	ADAP	0.056	0.34	0.00	9877
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	ADAP	0.06	-153.1	-	-0.47
2025-08-18	ADAP	0.07	-153.1	-	-0.47
2025-08-19	ADAP	0.06	-153.1	-	-0.47
2025-08-20	ADAP	0.06	-153.1	-	-0.47
2025-08-21	ADAP	0.06	-153.1	-	-0.47
2025-08-22	ADAP	0.06	-1080.0	-	-0.47
2025-08-25	ADAP	0.06	-1080.0	-	-0.47
2025-08-26	ADAP	0.06	-1080.0	-	-0.47
2025-08-27	ADAP	0.06	-1080.0	-	-0.47
2025-08-28	ADAP	0.07	-1080.0	-	-0.47
2025-08-29	ADAP	0.06	-1080.0	-	-0.47
2025-09-02	ADAP	0.06	-1080.0	-	-0.47
2025-09-03	ADAP	0.05	-1080.0	-	-0.47
2025-09-04	ADAP	0.05	-1080.0	-	-0.47
2025-09-05	ADAP	0.04	-1080.0	-	-0.47
2025-09-08	ADAP	0.04	-1080.0	-	-0.47
2025-09-09	ADAP	0.05	-1080.0	-	-0.47
2025-09-10	ADAP	0.05	-1080.0	-	-0.47
2025-09-11	ADAP	0.05	-1080.0	-	-0.47
2025-09-12	ADAP	0.05	-1080.0	-	-0.47
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	ADAP	-68.86	-40.42	3.54
2025-08-18	ADAP	-68.86	-42.99	3.50
2025-08-19	ADAP	-70.57	-42.99	3.50
2025-08-20	ADAP	-75.77	-42.99	3.50
2025-08-21	ADAP	-75.77	-42.99	3.50
2025-08-22	ADAP	-75.77	-42.99	3.50
2025-08-25	ADAP	-75.77	-23.22	3.27
2025-08-26	ADAP	-89.65	-23.22	3.27
2025-08-27	ADAP	-89.65	-23.22	4.34
2025-08-28	ADAP	-89.65	-23.22	4.34
2025-08-29	ADAP	-89.65	-23.22	4.34
2025-09-02	ADAP	-89.67	-28.30	4.34
2025-09-03	ADAP	-89.68	-28.30	4.34
2025-09-04	ADAP	-89.68	-28.30	4.34
2025-09-05	ADAP	-89.68	-28.30	4.34
2025-09-08	ADAP	-89.68	-28.30	4.34
2025-09-09	ADAP	-89.66	-28.30	4.34
2025-09-10	ADAP	-89.66	-28.30	4.34
2025-09-11	ADAP	-89.66	-28.30	9.85
2025-09-12	ADAP	-89.66	-28.30	9.85
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

-89.66

Institutional Transactions

-28.3

Beta

2.26

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.5

Max Drawdown 5-Year %

-99.6

Target Price

0.28

P/E

Forward P/E

PEG

P/S

0.23

P/B

P/Free Cash Flow

EPS

-0.66

Average EPS Est. Cur. Y

-0.47

EPS Next Y. (Est.)

-0.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-258.57

Relative Volume

1.67

Return on Equity vs Sector %

214.4

Return on Equity vs Industry %

227.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

Adaptimmune Therapeutics plc

Sector: Healthcare

Industry: Biotechnology

Employees: 506

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

stock quote shares ADAP – Adaptimmune Therapeutics plc Stock Price stock today

news today ADAP – Adaptimmune Therapeutics plc stock forecast ,stock prediction 2023 2024 2025

marketwatch ADAP – Adaptimmune Therapeutics plc yahoo finance google finance

stock history ADAP – Adaptimmune Therapeutics plc invest stock market

stock prices ADAP premarket after hours

ticker ADAP fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ADAP

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y